-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[ Hot attention from Chemical Machinery Equipment Network ] Recently, *(CMIF) disclosed the operation of China's machinery industry in 2020.
On the whole, the industry's prosperity has gradually recovered, especially since the third quarter of 2020, various economic indicators It rebounded sharply and continued a steady upward trend in the fourth quarter.
The growth rate of its industrial added value, operating income and total profit exceeded expectations.
From the perspective of industry classification, China's machinery industry mainly involves electrical machinery and equipment manufacturing, automobile manufacturing, * equipment manufacturing, general equipment manufacturing, and instrumentation manufacturing, which are five major industries, with a year-on-year increase of 8.
9% and 6.
6% respectively.
, 6.
3%, 5.
1% and 3.
4%.
Chemical machinery equipment network hotspots pay attention to chemical machinery equipment instruments and metersOn the whole, the industry's prosperity has gradually recovered, especially since the third quarter of 2020, various economic indicators It rebounded sharply and continued a steady upward trend in the fourth quarter.
The growth rate of its industrial added value, operating income and total profit exceeded expectations.
From the perspective of industry classification, China's machinery industry mainly involves electrical machinery and equipment manufacturing, automobile manufacturing, * equipment manufacturing, general equipment manufacturing, and instrumentation manufacturing, which are five major industries, with a year-on-year increase of 8.
9% and 6.
6% respectively.
, 6.
3%, 5.
1% and 3.
4%.
In the context of the recovery of China’s machinery industry, the pharmaceutical equipment industry, which is an important part of the machinery industry, has gradually resumed production and its operation has stabilized.
Many of the representative pharmaceutical machinery companies have achieved stable growth in 2020.
Profit growth doubled.
Many of the representative pharmaceutical machinery companies have achieved stable growth in 2020.
Profit growth doubled.
On the evening of February 26, Canaan Technology, a domestic solid preparation smart factory overall solution provider, released a 2020 annual performance report.
The revenue was about 1.
005 billion yuan, an increase of 42.
99% year-on-year; the net profit attributable to shareholders of listed companies was about 67.
6 million yuan , An increase of 31.
73% year-on-year; basic earnings per share was RMB 0.
26, an increase of 30% year-on-year.
Regarding the reasons for the growth in performance, Canaan Technology mentioned that during the reporting period, the company continued to strengthen the "solid preparation smart factory overall solution provider" and the strategic orientation of big health, and spared no effort to ensure the advancement of pharmaceutical equipment and smart logistics industry projects.
There was a substantial increase in the previous period.
The revenue was about 1.
005 billion yuan, an increase of 42.
99% year-on-year; the net profit attributable to shareholders of listed companies was about 67.
6 million yuan , An increase of 31.
73% year-on-year; basic earnings per share was RMB 0.
26, an increase of 30% year-on-year.
Regarding the reasons for the growth in performance, Canaan Technology mentioned that during the reporting period, the company continued to strengthen the "solid preparation smart factory overall solution provider" and the strategic orientation of big health, and spared no effort to ensure the advancement of pharmaceutical equipment and smart logistics industry projects.
There was a substantial increase in the previous period.
Specifically, Canaan Technology's solid preparation and powder process projects continue to maintain steady growth in 2020; pharmaceutical equipment smart factory business, biologics pharmaceutical water equipment and liquid dispensing system business, and the downstream application industry demand of the smart logistics business segment remain The strength has driven the rapid growth of revenue and orders in the above business segments.
At the same time, the company continued to steadily improve the operational efficiency of various businesses, optimize the revenue structure, and coordinate the development of upstream and downstream businesses across the industry chain to ensure that the company's sales and operating results continue to maintain steady growth.
Pharmaceutical water equipment At the same time, the company continued to steadily improve the operational efficiency of various businesses, optimize the revenue structure, and coordinate the development of upstream and downstream businesses across the industry chain to ensure that the company's sales and operating results continue to maintain steady growth.
No*Coincidentally, Chutian Technology, a domestic pharmaceutical equipment company, issued an announcement of performance increase in early February.
The company expects to realize net profit attributable to shareholders of listed companies of 182.
53 million yuan to 222.
64 million yuan in 2020, a year-on-year growth range of 180%-240%.
For the reasons for the growth in performance, Chutian Technology attributed it to the company's active response to customer needs during the reporting period and effectively guaranteed order delivery.
At the same time, the technology and product performance of each product line have been steadily improved, and competitive advantages have gradually emerged.
In addition, during the reporting period, the company completed the acquisition of ROMACO Group, which further promoted the strategic layout of corporatization.
The company expects to realize net profit attributable to shareholders of listed companies of 182.
53 million yuan to 222.
64 million yuan in 2020, a year-on-year growth range of 180%-240%.
For the reasons for the growth in performance, Chutian Technology attributed it to the company's active response to customer needs during the reporting period and effectively guaranteed order delivery.
At the same time, the technology and product performance of each product line have been steadily improved, and competitive advantages have gradually emerged.
In addition, during the reporting period, the company completed the acquisition of ROMACO Group, which further promoted the strategic layout of corporatization.
On January 29, 2021, Teflon, a service provider that aims to provide a systematic overall solution for pharmaceutical companies, disclosed a performance forecast.
The report shows that the net profit attributable to shareholders of listed companies in 2020 is expected to be about 452 million to 496 million yuan.
, A year-on-year increase of 210% to 240%; basic earnings per share of 0.
72 yuan to 0.
79 yuan.
During the reporting period, the company's net profit is expected to increase by 210% to 240% over the same period of the previous year.
The rapid growth of the company's performance in 2020 is mainly due to the development of new products, the company's strengthening of cost control and other factors.
The report shows that the net profit attributable to shareholders of listed companies in 2020 is expected to be about 452 million to 496 million yuan.
, A year-on-year increase of 210% to 240%; basic earnings per share of 0.
72 yuan to 0.
79 yuan.
During the reporting period, the company's net profit is expected to increase by 210% to 240% over the same period of the previous year.
The rapid growth of the company's performance in 2020 is mainly due to the development of new products, the company's strengthening of cost control and other factors.
Looking back at 2020, data shows that the total profit of the domestic pharmaceutical manufacturing industry was 350.
67 billion yuan, an increase of 12.
8% year-on-year, and the value-added of industries above designated size increased by 5.
9% year-on-year.
In the context of the accelerated development of the pharmaceutical manufacturing industry, the demand for the pharmaceutical industry, which is the upstream pharmaceutical industry, has gradually entered a stage of steady growth from a trough, with an increase in market share and an effective improvement in profitability.
At the same time, some pharmaceutical machinery companies are also actively deploying in the fields of biological medicine equipment and vaccine equipment, developing new products, expanding new areas, and gradually achieving some results.
In the context of rising raw material prices and labor costs, they have strengthened cost management and control.
, Continuously improve operating efficiency, and obtain a good performance report card.
67 billion yuan, an increase of 12.
8% year-on-year, and the value-added of industries above designated size increased by 5.
9% year-on-year.
In the context of the accelerated development of the pharmaceutical manufacturing industry, the demand for the pharmaceutical industry, which is the upstream pharmaceutical industry, has gradually entered a stage of steady growth from a trough, with an increase in market share and an effective improvement in profitability.
At the same time, some pharmaceutical machinery companies are also actively deploying in the fields of biological medicine equipment and vaccine equipment, developing new products, expanding new areas, and gradually achieving some results.
In the context of rising raw material prices and labor costs, they have strengthened cost management and control.
, Continuously improve operating efficiency, and obtain a good performance report card.
Looking forward to 2021, with the continued implementation of the general health strategy, the increasing awareness of people's health care, and the continuous upgrading of consumption levels, the market demand for pharmaceutical products is still expected to expand, which is expected to continue to drive the growth of domestic pharmaceutical equipment market demand.
At the same time, with the implementation of centralized procurement policies and new medical insurance, pharmaceutical companies are facing challenges in terms of production capacity, and the demand for pharmaceutical equipment will continue to expand.
However, some securities sources reminded that the overseas business expansion and revenue recognition/order signing of domestic pharmaceutical companies still have an adverse impact.
In addition, if the growth rate of the domestic pharmaceutical manufacturing industry declines, the demand for pharmaceutical equipment may decrease.
At the same time, with the implementation of centralized procurement policies and new medical insurance, pharmaceutical companies are facing challenges in terms of production capacity, and the demand for pharmaceutical equipment will continue to expand.
However, some securities sources reminded that the overseas business expansion and revenue recognition/order signing of domestic pharmaceutical companies still have an adverse impact.
In addition, if the growth rate of the domestic pharmaceutical manufacturing industry declines, the demand for pharmaceutical equipment may decrease.
Original title: The boom of China's machinery industry is gradually picking up, and the performance of pharmaceutical machinery is growing steadily
